io9’s AI cancer biomarker test outperforms NGS in new study data

Software company io9 has released data showing that its AI-powered biomarker test outperforms next-generation sequencing in first-line cancer treatment.

OncoGaze is an AI-based platform designed to identify biomarkers that can help determine the best initial treatment for cancer patients. DeepHRD is a specific biomarker test within the platform that detects homologous recombination deficiency (HRD), a genetic feature found in some cancers.